Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Canada Postdoctoral Research Award (CPRA) program

Direct Payment

$140,000.00

Developing peptide-specific immunotherapies for HLA-A*24/23

EF 2025-26

Résumé
Cancer treatments that harness the immune system, such as CAR T cell therapy, have revolutionized care for certain blood cancers but remain hard to develop without unwanted side effects. The difficulty is in finding "safe" targets-molecules that exist only on cancer cells and not on healthy tissues. This project focuses on a type of target called peptide-MHC complexes (pMHCs), which are small protein fragments displayed on the surface of nearly all cells and can reveal cancer-specific changes inside a tumor cell. Our team has created ImmunoVerse, a powerful tool that analyzes data collected from thousands of cancer tissue and healthy tissue samples to identify promising pMHC targets. Building on this, I developed Arcane24, a specialized library of custom-designed proteins that can precisely recognize cancer pMHCs common in large patient populations worldwide. Together, these innovations make it possible to find and target cancer-specific molecules that were previously inaccessible. By combining advanced protein engineering and immunology expertise, this research will generate new therapeutic candidates and diagnostic tools for cancers that currently have few treatment options. Ultimately, these advances could accelerate the development of safer, more effective immunotherapies, bringing personalized treatments to patients who need them most.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
537626
Name
Tang Qichen
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Developing peptide-specific immunotherapies for HLA-A*24/23
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Bispecific T Cell Engagers (Bites); Chimeric Antigen Receptor (Car); Class I Major Histocompatibility Complex (Mhc-I); Human Leukocyte Antigen (Hla); Pan-Cancer; Phage Display; Prostate Cancer
Abstract
Cancer treatments that harness the immune system, such as CAR T cell therapy, have revolutionized care for certain blood cancers but remain hard to develop without unwanted side effects. The difficulty is in finding "safe" targets-molecules that exist only on cancer cells and not on healthy tissues. This project focuses on a type of target called peptide-MHC complexes (pMHCs), which are small protein fragments displayed on the surface of nearly all cells and can reveal cancer-specific changes inside a tumor cell. Our team has created ImmunoVerse, a powerful tool that analyzes data collected from thousands of cancer tissue and healthy tissue samples to identify promising pMHC targets. Building on this, I developed Arcane24, a specialized library of custom-designed proteins that can precisely recognize cancer pMHCs common in large patient populations worldwide. Together, these innovations make it possible to find and target cancer-specific molecules that were previously inaccessible. By combining advanced protein engineering and immunology expertise, this research will generate new therapeutic candidates and diagnostic tools for cancers that currently have few treatment options. Ultimately, these advances could accelerate the development of safer, more effective immunotherapies, bringing personalized treatments to patients who need them most.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Tang, Qichen
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~